1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 12 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2006Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancerDelea, T.; Karnon, J.; Smith, R.; Johnston, S.; Brandman, J.; Sung, J.; Goss, P.
2013A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in AustraliaHajiali Afzali, H.; Gray, J.; Beilby, J.; Holton, C.; Karnon, J.
2005Developing a relativities approach to valuing the prevention of non-fatal work-related accidents and ill healthKarnon, J.; Tsuchiya, A.; Dolan, P.
2012Applying risk adjusted cost-effectiveness (RAC-E) analysis to hospitals: estimating the costs and consequences of variation in clinical practiceKarnon, J.; Caffrey, O.; Pham, C.; Grieve, R.; Ben-Tovim, D.; Hakendorf, P.; Crotty, M.
2013A risk-adjusted economic evaluation of alternative models of involvement of practice nurses in management of type 2 diabetesHajiali Afzali, H.; Gray, J.; Beilby, J.; Holton, C.; Banham, D.; Karnon, J.
2005Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UKKarnon, J.; Brennan, A.; Pandor, A.; Fowkes, G.; Lee, A.; Gray, D.; Coshall, C.; Nicholls, C.; Akehurst, R.
2012Home videophones improve direct observation in Tuberculosis treatment: a mixed methods evaluationWade, V.; Karnon, J.; Eliott, J.; Hiller, J.; Neyrolles, O.
2012The cost of treating advanced non-small cell lung cancer: estimates from the Chinese experienceZeng, X.; Karnon, J.; Wang, S.; Wu, B.; Wan, X.; Peng, L.; de Mello, R.A.
2006Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: The UK perspectiveKarnon, J.; Delea, T.; Johnston, S.; Smith, R.; Brandman, J.; Sung, J.; Goss, P.
2009Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus CyclophosphamideLiubao, P.; Xiaomin, W.; Chongqing, T.; Karnon, J.; Gannong, C.; Jianhe, L.; Wei, C.; Xia, L.; Junhua, C.

Discover